DL-TBOA inhibited [14C] glutamate uptake in COS-1 cells expressing human EAAT1 and EAAT2, with Ki values of 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner, with Ki values of 4.4 μM and 3.2 μM, respectively. DL-TBOA is an effective non-transportable excitatory amino acid transporter inhibitor with IC50 of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter 1 (EAAT1, EAAT2 and EAAT3), respectively.

DL-TBOA reversed the loss of viability caused by oxaliplatin. DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment can reduce the induction of p53 by SN38 and oxaliplatin. DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhanced SN38-induced loss of vitality.

205309-81-5

C11H13NO5

239.22

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years